BostonGene is a Massachusetts-based biotechnology company and a Category Award Winner for Business Expansion, Innovation and Product Launches in the 2023 Clinical Trials Arena Excellence Awards.

Powered by artificial intelligence (AI), BostonGene provides comprehensive molecular and immune profiling for clinical and research applications in precision medicine. The company won three categories – Business Expansion, Innovation, and Product Launches – in the 2023 Clinical Trials Arena Excellence Awards.

During the award consideration period, the company made significant strides to advance personalised therapies and improve outcomes for cancer patients and those with other immune-related diseases.

Andrew Feinberg, President and CEO of BostonGene, remarked, “BostonGene is deeply honoured to receive these awards from GlobalData. These awards not only showcase our accomplishments but also our momentum moving forward as we continue to capitalise on our AI-driven diagnostic technologies to facilitate drug development and treatment selection.”

Business expansion award for BostonGene

BostonGene expansion

BostonGene launched CLIA-certified and CAP-accredited Liquid Biopsy, Immunoprofiling, and Spatial Proteomics solutions to complement the BostonGene Tumor PortraitTM next-generation sequencing (NGS)-based laboratory-developed test. Together, these platforms deliver a comprehensive view of each patient’s disease through integrative tissue- and blood-based profiling techniques. By accounting for malignant cells, the tumor microenvironment, and host immunity, BostonGene’s offerings support discovery, translational, and clinical efforts in precision oncology. During the award period, BostonGene also announced the BEGIN study, a clinical trial with a US-based community oncology research network designed to bring personalised medicine to community settings.

BostonGene harnesses transcriptomics, genomics, immunoprofiling, multiplex immunofluorescence (MxIF), and other platforms for multiparametric predictive biomarker discovery during drug development. A clinical-stage biopharmaceutical company recently selected BostonGene as their genomic partner to support the first-in-human Phase I/II study of a TROP2-directed antibody-drug conjugate in patients with advanced cancers at leading cancer institutions across North America. BostonGene’s solutions address an unmet need for tools in biomarker discovery and clinical trial support during drug development, as many biopharma companies lack the in-house resources for integrated big data analysis.

Outside of the US, BostonGene launched several initiatives to expand its global presence, forging strategic partnerships and collaborations worldwide. Notably, BostonGene formed a joint venture (JV) in Japan with an IT industry leader and a private equity firm aimed at streamlining drug development and advancing precision medicine using BostonGene’s AI-driven molecular profiling and bioanalytics. BostonGene also recently partnered with an Australian company to uncover novel diagnostic biomarkers of follicular lymphoma. In the breast oncology space, BostonGene established collaborations in the US and Japan focused on refining HER2 status in the wake of recent drug approvals for patients with HER2-low breast cancers. These initiatives showcase BostonGene’s transformative innovations and global impact in precision medicine.

Innovation award for BostonGene’s AI-based cell deconvolution and clinical trial matching algorithms

BostonGene Kassandra

BostonGene was chosen as the overall winner in the Innovation category for the groundbreaking Kassandra™ machine learning (ML) algorithm for bulk RNA-seq cell type deconvolution and a proprietary AI-driven clinical trial matching algorithm. Implemented as a component of BostonGene’s Tumor PortraitTM test, Kassandra™ was trained and proven to precisely reconstruct the tumour microenvironment. KassandraTM identifies and quantifies more than 50 distinct subpopulations, including PD-L1+ and regulatory T cells, critical biomarkers for clinical decision-making in precision medicine.

Another component of the BostonGene Tumor PortraitTM test, BostonGene’s AI-driven clinical trial matching algorithm is a fully automated scoring mechanism that provides personalised clinical trial recommendations for patients by accounting for more than 80 dynamic parameters. These innovations demonstrate BostonGene’s commitment to supporting clinical decision-making for physicians and, ultimately, transforming the standard of care for cancer patients.

Product Launches award for BostonGene’s Liquid Biopsy assay

Liquid Biopsy assay BostonGene

BostonGene won in the Product Launches category for the development of a new Liquid Biopsy assay. The CLIA-certified and CAP-accredited test detects clinically actionable gene alterations to predict and monitor disease progression and treatment response. From a routine blood sample, BostonGene interrogates 216 well-characterised biomarkers useful for treatment selection and response prediction. In-house proprietary error reduction algorithms and filtration of clonal hematopoiesis of indeterminate potential (CHIP) mutations minimise false positive diagnostic results, ensuring high assay specificity. BostonGene’s liquid biopsy assay can facilitate treatment selection and monitor minimal residual disease.

Company Profile

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases.  BostonGene’s concierge-service model provides customised client solutions using a multi-omic approach prioritised for real-world impact to optimise standard-of-care therapies, accelerate research and provide cost-effective, measurable data-driven results.  BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalised roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at

Contact details

University Office Park III

95 Sawyer Road, Suite 500

Waltham, MA 02453

+1 617-658-4545